XTalks

MAY 9, 2024

Genmab, a trailblazer in the field of antibody therapeutics, celebrates this milestone by reflecting on its impressive journey from a small-scale startup to a global leader in cancer treatment and beyond. Since then, innovative science has been at Genmab’s core, as we harness the power of human antibodies to improve the lives of patients.

Antibody 52

Antibody Clinical Trials Clinical Trials Medicine 52

Bio Pharma Dive

SEPTEMBER 21, 2021

Tivdak, a type of drug known as an antibody-drug conjugate, is the fourth approved medicine for Seagen and its third to reach market since December 2019.

FDA Approval 279

FDA Approval Drugs Antibody Medicine 279

Drug Discovery World

MAY 1, 2024

DDW’s Megan Thomas speaks to industry experts and thought leaders about the potential for therapeutic antibodies in 2024. Many of the best-selling drugs in 2023 were monoclonal antibody (mAB) therapies, including Keytruda (pembrolizumab), Humira (adalimumab), and Dupixent (dupilumab) 1.

Antibody 59

Antibody FDA Approval Drugs Development 59

Bio Pharma Dive

JULY 14, 2023

billion to acquire the private biotech and its experimental antibody, which Lilly plans to pair with its own weight loss medicines. The pharma will pay up to $1.9

Antibody 246

Antibody Drugs Medicine 246

Drug Discovery World

MARCH 12, 2024

DDW’s Megan Thomas speaks to experts from the drug discovery industry about their predictions on what 2024 holds for our sector. Here, experts weigh in on the future of monoclonal antibodies (mAbs). Amanda Halford, President Bioprocess, Cytiva “In 2024, the emphasis will remain on novel mAbs, specifically antibody drug conjugates.

Antibody 81

Antibody FDA Approval Drugs Development 81

STAT News

NOVEMBER 30, 2022

The Food and Drug Administration on Wednesday ended its emergency authorization for the only remaining Covid-19 antibody therapy cleared for use, saying variants that render it ineffective are now dominant in the United States. have been growing in prevalence. Read the rest…

Antibody 111

Antibody Medicine Drugs 111

Drug Discovery World

APRIL 8, 2024

Dr O’Donnell-Tormey will address the opportunities, innovations and challenges in the therapeutic antibody space. Dr Levy will outline the significance of belimumab, a monoclonal antibody that inhibits B-cell activating factor. What effect has antibody engineering had on drug discovery and development?

Antibody 59

Antibody Marketing Gene Therapy Engineer 59

Drug Discovery World

APRIL 22, 2024

Join DDW for this free event ‘ Where is the opportunity in the therapeutic antibody market? ’, which is co-sponsored by Bio-Rad and Benchling. Dr Milind Nigam will discuss the role of software in accelerating the pace of discovery of antibody therapeutics. What effect has antibody engineering had on drug discovery and development?

Antibody 52

Antibody Development Gene Therapy Marketing 52

Drug Discovery World

APRIL 29, 2024

Join DDW for this free event ‘ Where is the opportunity in the therapeutic antibody market? ’, which is co-sponsored by Bio-Rad and Benchling. Dr Milind Nigam will discuss the role of software in accelerating the pace of discovery of antibody therapeutics. What effect has antibody engineering had on drug discovery and development?

Antibody 52

Antibody Marketing Gene Therapy Engineer 52

Pharmaceutical Technology

MARCH 9, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: Tumour antibody serum compositions. The production of antibodies in response to proteins expressed during cancer development serves as a biomarker.

Antibody 147

Antibody Production Protein Regulation 147

Bio Pharma Dive

APRIL 3, 2024

The buyout continues a surge in M&A for developers of antibody-drug conjugates and gives Genmab a potential competitor to a medicine AbbVie recently purchased in a multibillion-dollar acquisition.

Antibody 171

Antibody Medicine Development Drugs 171

Drug Discovery World

APRIL 15, 2024

Join DDW for this free event ‘ Where is the opportunity in the therapeutic antibody market? ’, which is co-sponsored by Bio-Rad and Benchling. Dr Milind Nigam will discuss the role of software in accelerating the pace of discovery of antibody therapeutics. What effect has antibody engineering had on drug discovery and development?

Antibody 52

Antibody Marketing Gene Therapy Engineer 52

Pharmaceutical Technology

APRIL 13, 2023

Clinical-stage biopharmaceutical firm Alentis Therapeutics has raised $105m in a Series C financing round for advancing transformational medicines targeting the CLAUDIN-1 protein. ALE.F02 is being developed for the treatment of advanced kidney, lung and liver fibrosis while ALE.C04 is a potential treatment to target CLDN1-positive tumours.

Medicine 130

Medicine Development Antibody Engineer 130

Pharmaceutical Technology

MAY 8, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: Monoclonal antibody conjugates for cancer treatment.

Antibody 130

Antibody Drugs Development Medicine 130

Bio Pharma Dive

FEBRUARY 15, 2024

Armed with $94 million in funding, the biotech is marrying antibody-drug conjugates with protein degraders to create a new kind of cancer medicine.

Protein 183

Protein Antibody Medicine Drugs 183

Drug Discovery World

APRIL 8, 2024

Join DDW for this free event ‘ Where is the opportunity in the therapeutic antibody market? ’, which is co-sponsored by Bio-Rad and Benchling. Dr Milind Nigam will discuss the role of software in accelerating the pace of discovery of antibody therapeutics. What effect has antibody engineering had on drug discovery and development?

Antibody 52

Antibody Marketing Gene Therapy Engineer 52

Bio Pharma Dive

OCTOBER 26, 2022

The treatment, which will be sold as Tecvayli, is the first bispecific antibody cleared for the disease. It joins a group of medicines on market that target a protein called BCMA.

Protein 284

Protein Antibody Medicine Drugs 284

Bio Pharma Dive

APRIL 14, 2023

Newly launched TORL BioTherapeutics wants to develop a variety of antibody drugs, and comes equipped with $158 million as well as a close partnership with the lab of pioneering breast cancer researcher Dennis Sloman.

Medicine 171

Medicine Antibody Development Drugs 171

Pharmaceutical Technology

NOVEMBER 20, 2022

This news came as many organisations and patient advocacy groups have been campaigning for the adoption of some of the rejected drugs for several months, amidst concerns about access to medicines in the UK. NICE’s technology appraisals calculate appropriate costs for drugs using the incremental cost-effectiveness ratio (ICER).

Drugs 279

Drugs Medicine Antibody Clinical Trials 279

Bio Pharma Dive

APRIL 3, 2023

The biotech is expanding its cancer medicine pipeline by licensing two experimental antibody drug conjugates from Shanghai-based Duality.

Licensing 287

Licensing Licensing Antibody Medicine 287

Bio Pharma Dive

OCTOBER 20, 2022

The deal gives AbbVie an experimental medicine for idiopathic pulmonary fibrosis, as well as a platform for designing antibody drugs that can target proteins known as GPCRs.

Protein 321

Protein Antibody Medicine Drugs 321

Bio Pharma Dive

MARCH 23, 2023

The two companies gained billions of dollars in market value after their antibody drug succeeded against a disease that’s been difficult to treat with biologic medicines.

Trials 280

Trials Antibody Medicine Marketing 280

pharmaphorum

MAY 30, 2022

pharmaphorum sat down with Sunil Verma, global head of oncology, medical, at AstraZeneca, to discuss three studies that were presented at the show, which demonstrate a few of the ways oncology is advancing through precision medicine and targeted therapies. That antibody-drug conjugate then docks on the cancer cell receptor.

Antibody 115

Antibody Drugs Medicine Research 115

Drug Discovery World

JANUARY 4, 2024

Ampersand Biomedicines has announced the acquisition of antibody discovery technology company AbCheck, previously a wholly-owned subsidiary of Affimed. The post Ampersand Biomedicines acquires antibody discovery company appeared first on Drug Discovery World (DDW).

Antibody 52

Antibody Medicine Drugs 52

Bio Pharma Dive

MAY 18, 2021

The pharma acquired rights to an experimental antibody medicine that blocks a protein, called TIGIT, that's become a focus for several cancer drugmakers.

Protein 333

Protein Antibody Medicine Drugs 333

Pharmaceutical Technology

APRIL 5, 2023

Absci has collaborated with bioinformatics firm M2GEN to expedite the development of new cancer medicines. Absci stated that this collaboration combines AI drug creation technology and oncology bioinformatics, thereby reducing the time and cost of cancer drug development.

Development 130

Development Bioinformatics Drugs Immune Response 130

Bio Pharma Dive

JUNE 6, 2023

Agency scientists raised no major red flags in their review of the antibody medicine in documents posted ahead of a Thursday meeting of FDA advisers.

Antibody 177

Antibody Scientist Medicine Drugs 177

XTalks

DECEMBER 12, 2023

Plasma medicine is a critical and specialized field within healthcare, centering on the use of human plasma for the development and administration of life-saving treatments. Human plasma, the clear, liquid portion of blood, is composed of water, electrolytes, nutrients and crucial proteins such as antibodies, clotting factors and albumin.

Medicine 111

Medicine Recombinant Antibody Protein Antibody 111

Bio Pharma Dive

NOVEMBER 30, 2023

The acquisition of ImmunoGen gives AbbVie an approved medicine for ovarian cancer, and continues a pharma spending spree on antibody-drug conjugates.

Antibody 156

Antibody Medicine Drugs 156

Pharmaceutical Technology

AUGUST 18, 2022

Atomwise and Sanofi have entered a strategic and exclusive research partnership to use the former’s artificial intelligence (AI)-driven AtomNet platform to discover and research up to five drug targets computationally. The post Atomwise and Sanofi partner for drug discovery using AI appeared first on Pharmaceutical Technology.

Drugs 246

Drugs Engineer Medicine Sales 246

Drug Discovery World

APRIL 14, 2023

Oliver Schon, PhD, is VP Research & Development at BiVictriX Therapeutics, a UK-based emerging drug discovery and development company generating a pioneering first-in-class next-generation ADC anti-cancer therapeutics which exhibit superior selectivity towards cancer.

Antibody 52

Antibody Development Drugs Manufacturing 52

Bio Pharma Dive

JUNE 28, 2023

The companies aim to seek an FDA nod for their bispecific antibody, Epkinly, in follicular lymphoma, where it would compete with a recently approved Roche medicine.

Antibody 148

Antibody Medicine Drugs 148

Drug Discovery World

MARCH 8, 2024

Biopharmaceutical company Innovent Biologics has launched the first-in-human (FIH) Phase I clinical trial of IBI3002, a novel bispecific antibody targeting Interleukin 4 receptor α (IL-4Rα) and thymic stromal lymphopoietin (TSLP). In vitro assays have shown superiority over the marketed monoclonal antibodies to respective target.

Antibody 52

Antibody Trials In-Vitro Clinical Trials 52

Medical Xpress

NOVEMBER 9, 2022

A new approach to stem cell therapy that uses antibodies instead of traditional immunosuppressant drugs robustly preserves cells in mouse brains and has potential to fast-track trials in humans, a Michigan Medicine study suggests.

Antibody 98

Antibody Medicine Trials Drugs 98

pharmaphorum

MAY 18, 2022

Brand new UK startup RQ Biotechnology has been thrust into the spotlight after signing a $157 million licensing deal with AstraZeneca for monoclonal antibodies intended to protect vulnerable and immunosuppressed people from COVID-19. ” The post AstraZeneca buys into startup RQ Bio’s COVID antibodies appeared first on. .

Antibody 95

Antibody Licensing Licensing Medicine 95

Bio Pharma Dive

SEPTEMBER 16, 2022

If authorized by the European Commission, the companies’ antibody medicine would become the first cleared for broad use in newborns and infants.

Antibody 177

Antibody Medicine Drugs 177

Drug Discovery World

JULY 24, 2023

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended conditional marketing authorisation for Janssen’s Talvey (talquetamab). The post CHMP recommendation for bispecific antibody talquetamab appeared first on Drug Discovery World (DDW).

Antibody 52

Antibody Licensing Licensing Medicine 52